Re: Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums
Paul,
Hopefully you will be overwhelmed keeping up with new cancer treatments over the next few years! Did you see all the treatments in the pipeline at Novartis?
I searched for Neoadjuvant trials a few months ago at clinicaltrials.gov and was just blown away at how many there were.
When do you expect any treatments that use targets other than the HER1-4 or ER+ to be approved?
|